Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.
Trial locations(12 sites)
China
Beijing Cancer hospital, Beijing, Beijing Municipality Fujian Cancer Hospital, Fuzhou, Fujian Guangdong Provincial People's Hospital, Guangzhou, Guangdong Peking University Shenzhen Hospital, Shenzhen, Guangdong Local Institution - 0006, Harbin, Heilongjiang